Bristol-Myers Squibb Co (BMY)
49.00
-0.14
(-0.28%)
USD |
NYSE |
Apr 23, 16:00
49.02
+0.02
(+0.04%)
After-Hours: 20:00
Bristol-Myers Squibb SG&A Expense (Quarterly): 2.073B for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.073B |
September 30, 2023 | 2.003B |
June 30, 2023 | 1.934B |
March 31, 2023 | 1.762B |
December 31, 2022 | 2.266B |
September 30, 2022 | 1.93B |
June 30, 2022 | 1.787B |
March 31, 2022 | 1.831B |
December 31, 2021 | 2.354B |
September 30, 2021 | 1.788B |
June 30, 2021 | 1.882B |
March 31, 2021 | 1.666B |
December 31, 2020 | 2.721B |
September 30, 2020 | 1.706B |
June 30, 2020 | 1.628B |
March 31, 2020 | 1.606B |
December 31, 2019 | 1.734B |
September 30, 2019 | 1.055B |
June 30, 2019 | 1.076B |
March 31, 2019 | 1.006B |
December 31, 2018 | 1.336B |
September 30, 2018 | 1.104B |
June 30, 2018 | 1.131B |
March 31, 2018 | 980.00M |
December 31, 2017 | 1.316B |
Date | Value |
---|---|
September 30, 2017 | 1.163B |
June 30, 2017 | 1.187B |
March 31, 2017 | 1.085B |
December 31, 2016 | 1.463B |
September 30, 2016 | 1.163B |
June 30, 2016 | 1.263B |
March 31, 2016 | 1.09B |
December 31, 2015 | 1.55B |
September 30, 2015 | 1.224B |
June 30, 2015 | 1.171B |
March 31, 2015 | 1.056B |
December 31, 2014 | 2.104B |
September 30, 2014 | 1.228B |
June 30, 2014 | 1.183B |
March 31, 2014 | 1.184B |
December 31, 2013 | 1.349B |
September 30, 2013 | 1.211B |
June 30, 2013 | 1.361B |
March 31, 2013 | 1.183B |
December 31, 2012 | 1.51B |
September 30, 2012 | 1.241B |
June 30, 2012 | 1.228B |
March 31, 2012 | 1.196B |
December 31, 2011 | 1.511B |
September 30, 2011 | 1.224B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.055B
Minimum
Sep 2019
2.721B
Maximum
Dec 2020
1.832B
Average
1.788B
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Amgen Inc | 2.274B |
Gilead Sciences Inc | 1.608B |
Johnson & Johnson | 5.257B |
Karuna Therapeutics Inc (DELISTED) | 47.39M |
2seventy bio Inc | 16.20M |